Martin Bergstrand, Ph.D.

Principal Consultant & MIDD Platform Scientific Lead

Portrait-of-Martin-Bergstrand_Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects, serving as MIDD Platform Scientific Lead
  • Expertise includes trial design, pharmacometrics (especially complex pharmacokinetics, mechanism based PKPD and Markov models), and model informed drug development in therapeutic areas such as infectious, metabolic, and cardiovascular diseases
  • Previously worked as part-time Researcher at Uppsala University, Sweden, where he performed pharmacometric research primarily by supervision of Ph.D. students, as Visiting Scientist at Mahidol-Oxford Tropical Medicine Research Unit, Thailand, and Clinical Pharmacology Scientist at AstraZeneca R&D Mölndal, Sweden
  • M.Sc. in Biomedicine (2003) from University of Kalmar, Sweden, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Exposure-response analysis for time-to-event data in the presence of adaptive dosing: efficient approaches and pitfallsDose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case StudyThe evolving role of in vitro – in vivo correlation in Model-Informed Drug Development: A multi-stakeholder perspectiveExposure-response analysis for time-to-event data in the presence of adaptive dosing: efficient approaches and pitfalls (Poster)Population pharmacokinetic analysis of doxecitine and doxribtimine in patients with thymidine kinase 2 deficiency and in healthy volunteersExpediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patientsThe Reference-Corrected Visual Predictive Check: A More Intuitive Diagnostic for Non-Linear Mixed Effects ModelsA tutorial on pharmacometric Markov modelsThe reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationshipsPhase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEKA workflow for comparing drug candidates based on Probability of Pharmacological Success (PoPS)